Antibacterial activity of Chamaecyparis obtuse extract and Profile of Antimicrobial Agents Resistance for Metallo-β-lactamase-Producing Pseudomonas aeruginosa

In vitro antimicrobial activities of hot water extracts of Chamaecyparis obtuse, for clinical metallo-β-lactamase-Producing Pseudomonas aeruginosa (MBLPA.) was compared to commonly used conventional antimicrobial agents. All MBLPA was susceptible to colistin or amikacin, but also to imipenem 88.6%, meropenem 100%, piperacillin 85.7%, ceftazidime 97.1%, gentamicin 97.1%, and ciprofloxacin 100% were non-susceptible. MIC range to imipenem, meropenem, cefotaxime, ceftazidime, gentamicin, and ciprofloxacin for MBLPA were each 1 - >128 ㎍/mL, 4 - >128 ㎍/mL, 4 - >128 ㎍/mL, 8 - >128 ㎍/mL, 4 - >128, and 2- >128 ㎍/mL. MIC range to aztreonam for MBLPA were 1 - 128 ㎍/mL. MIC₉₀ to imipenem, meropenem, cefotaxime, ceftazidime, gentamicin, and ciprofloxacin for MBLPA were each 32 ㎍/mL, >128 ㎍/mL, >128 ㎍/mL, >128 ㎍/mL, >128 ㎍/mL, and 128 ㎍/mL. MIC₉₀ to colistin and amikacin were each 1 ㎍/mL and 64 ㎍/mL. The hot water extracts of C. obtuse leaf had the lowest MIC range (0.25 - >0.5 μL/mL), MIC₅₀ (>0.5 μL/mL), and MIC₉₀ (>0.5 μL/mL) of the clinical MBLPA tested, and it was possible more potent than various conventional antimicrobial agents for MBLPA infection patients. Therefore, it suggested the possibility of using extract components of C. obtuse or their derivatives to treat MBLPA infection patients.